Valneva Scotland announces year-long support for local cancer charity Team Jak
The company’s workforce will volunteer and fundraise for Team Jak throughout the year
Read Moreby Emily Kimber | Oct 22, 2024 | News | 0
The company’s workforce will volunteer and fundraise for Team Jak throughout the year
Read Moreby John Pinching | Jun 13, 2023 | News | 0
VLA1553 had a high seroresponse rate among participants 28 days after receiving a single administration
Read Moreby John Pinching | Mar 2, 2023 | News | 0
European Medicines Agency has issued a positive opinion for the use of VLA2001 among certain adults
Read Moreby John Pinching | Feb 20, 2023 | News | 0
VLA1553 is a single-dose, live-attenuated vaccine candidate targeting the highly dangerous chikungunya virus
Read Moreby John Pinching | Feb 14, 2023 | News | 0
Phase 3 trial of single-shot chikungunya vaccine candidate unfolds among an adolescent cohort
Read Moreby John Pinching | Jan 3, 2023 | News | 0
Company has reported booster details from a study of its inactivated COVID-19 candidate
Read Moreby John Pinching | Dec 5, 2022 | News | 0
99% of participants retained very high neutralising antibody levels 12 months after treatment
Read Moreby John Pinching | Dec 1, 2022 | News | 0
Children and adults have been treated using the Lyme disease antibody candidate VLA15
Read Moreby John Pinching | Sep 8, 2022 | News | 0
Collaboration involves the marketing and distribution of PreHevbri across Europe
Read Moreby John Pinching | Feb 25, 2022 | News | 0
Valneva expects to receive a positive CHMP recommendation for the conditional approval of its VLA2001 vaccine
Read Moreby Lucy Parsons | Sep 13, 2021 | News | 0
Gov has alleged that the company breached its obligations under the agreement
Read Moreby Lucy Parsons | Aug 23, 2021 | News | 0
VLA2001 is an inactivated, adjuvanted vaccine candidate
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
